An early move to reduce the price of F2 medicines by manufacturer, GlaxoSmithKline (GSK), will help minimise stock shortages over Easter, the Pharmacy Guild of Australia believes.
With mandatory price disclosure for all medicines listed on the F2 formulary set for 1 April, GSK has announced it will cut prices from 1 March, to assist pharmacists deal with stock management, issues.
Welcoming the announcement, a Guild spokesperson told Pharmacy News it was a “responsible action”.
“We think that it’s a welcome and responsible action from GSK, in trying to assist the proper stock management of medicines at a very precarious time,” the spokesperson said.
“It should smooth out some of the problems which are widely expected on 1 April.”
The GSK medicines affected by price...
This site is intended for Registered Medical Practitioners.
To make the most of Pharmacy News, you need to be logged in.